Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Florida: - Holy Cross Hospital — Fort Lauderdale, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Miami Cancer Institute — Miami, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Memorial Hospital West — Pembroke Pines, Florida
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Florida: - Mayo Clinic in Florida — Jacksonville, Florida
- Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…
Sponsor: BeOne Medicines
NCT ID: NCT05100862
Sites in Florida: - Baptist Md Anderson Cancer Center — Jacksonville, Florida
- Ascension Sacred Heart — Pensacola, Florida
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Florida: - Clermont Oncology Center ( Site 0046) — Clermont, Florida
- Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Florida Cancer Specialists - East ( Site 7002) — West Palm Beach, Florida
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Florida: - University of Florida (Adults and Pediatrics) — Gainesville, Florida
- University of Miami/Jackson Memorial Hospital (Adults only) — Miami, Florida
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Florida: - Memorial Cancer Institute, Memorial Healthcare System — Pembroke Pines, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in Florida: - Local Institution - 0008 — Jacksonville, Florida
- Local Institution - 0214 — Tampa, Florida
- Local Institution - 0217 — Tampa, Florida
Phase 2, Phase 3 Recruiting Industry
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05139017
Sites in Florida: - Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163) — Boca Raton, Florida
- Clermont Oncology Center ( Site 0174) — Clermont, Florida
- BRP-Hialeah Hospital ( Site 0182) — Hialeah, Florida
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Sites in Florida: - Mayo Clinic Cancer Center — Jacksonville, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Florida: - University of Miami — Coral Gables, Florida
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Florida: - Florida Cancer Specialists — Fort Myers, Florida
- Cancer Specialists of North Florida -St Augustine — Saint Augustine, Florida
- Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Sites in Florida: - Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute — Pembroke Pines, Florida
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or margina…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in Florida: - Boca Raton Clinical Research (BRCR) Global — Plantation, Florida
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in Florida: - GC2202 Study Site 103 — St. Petersburg, Florida
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Sites in Florida: - Study Site 102 — St. Petersburg, Florida
Phase 3 Recruiting Academic/Other
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New…
Sponsor: University College, London
NCT ID: NCT04685616
Sites in Florida: - University of Miami School of Medicine — Miami, Florida
Phase 3 Recruiting Industry
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal ly…
Sponsor: Aldeyra Therapeutics, Inc.
NCT ID: NCT07402876
Sites in Florida: - Bascom Palmer Eye Institute — Miami, Florida
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- Nicklaus Children's Hospital — Miami, Florida
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Florida: - UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- AdventHealth Orlando — Orlando, Florida
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Florida: - Mount Sinai Medical Center Campus — Miami Beach, Florida
- The Oncology Institute — North Miami Beach, Florida
- Mid Florida Hematology Oncology — Orange, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Florida: - Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-…
Sponsor: Genmab
NCT ID: NCT05283720
Sites in Florida: - Tampa General Hospital /ID# 246748 — Tampa, Florida
Phase 2 Recruiting Industry
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT ID: NCT04920617
Sites in Florida: - Boca Raton Regional Hospital — Boca Raton, Florida
- BRCR Medical Center Inc. — Hollywood, Florida
- BRCR Medical Center Inc. — Plantation, Florida
- Comprehensive Hematology and Oncology — St. Petersburg, Florida